Magnesium Oral Supplementation for Acute Non-specific Low Back Pain

• Status: Completed
• Trial end date: 2020-03-08
• Target enrollment: 0
• Participant gender: All

Summary

Acute non-specific low back pain (LBP) is one of the most common complaints at the emergency department. It is more prevalent in countries with high-income economies, where 60-80% of the population report back pain at some point in their life. Numerous medication options are available for acute LBP relief such as non-steroid anti-inflammatory drugs (NSAIDs), myorelaxant drugs, opioids, and benzodiazepines. Magnesium is a physiological voltage-dependent blocker of N-methyl-D-aspartate NMDA)-coupled channels that can influence inflammatory pain and neuropathic pain through several different mechanisms. In this study the investigators aimed to investigate the effect of magnesium oral supplementation for acute low back pain.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Istanbul University
• Treatments: Acetaminophen; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal

Criteria

Inclusion Criteria:

• patients aged>18 years old,

• initiation of acute low back pain in the 10 days prior to study entry and functionally impairing low back pain, which we defined as a score of > 5 on the Roland-Morris Disability Questionnaire (RMDQ).

Exclusion Criteria:

• aged>65 years old,

• history of trauma,

• radicular pain, which we defined as pain radiating below the gluteal folds,

• history of vertebral tumor or metastasis,

• patients who were pregnant or lactating,

• unavailable for follow-up,

• with allergy or contraindication to the investigational medications,

• chronic analgesic use,

• autoimmune diseases or inflammatory rheumatic disorders,

• cardiopulmonary restrictions,

• severe kidney or liver function disorders and prior surgery on the lumbar spine.